MediPharm Labs Corp. announced that Harvest Medicine's study entitled, "Self-Reported Effects of Illness Severity, Depression and Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series" has been published in the peer-reviewed American Journal of Endocannabinoid Medicine. Harvest Medicine Inc. includes a medical clinic network, and is a wholly owned subsidiary of MediPharm Labs.

The retrospective study was led by HMED and reviewed data from 805 patients who indicated fibromyalgia as a primary reason for seeking medical cannabis and had a minimum of one follow-up assessment. Details on the study can be viewed on American Journal of Endocannabinoids Website. MediPharm remains focused on investing in clinical research and supporting the development of future cannabis derived pharmaceutical drugs.

Consistent with this commitment, the Company continues to supply sponsors and investigators with cannabis-derived study drugs, placebos, and other services and assistance as may be required during the course of the studies. Summary of MediPharm Labs Clinical Projects: Res researcher: Indication: Indication: Recent Milestone: McMaster University: Treatment of post-surgical pain; Two:CTM delivered and |enrollment in First Quarter 2023; Patient dosing; Commenced in Second Quarter 2023; University Health; Improving Pain Disability with Pilot |CTM Delivered and Network - Toronto - Toronto - the Use of Oral Cannabinoids |enrollment clinic in First Quarter 2023; CM | |shipment in First Quarter 2023; and University Health - Improving Pain Disability with |Pilot |CTM Delivered and network - Toronto - the Use of oral Cannabinoids |en enrollment clinic in First Quarter 2023.CTM | |shipment in first quarter 2023. CM |shipment in first quarter of 2023.